AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02078427 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADVATE
Description: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Study NCT02078427 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADYNOVI
Description: Antihemophilic Factor (Recombinant) Pegylated
Study NCT03052218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
Study NCT04096508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Patients sit comfortably in a chair for 20 min listening music before the procedure.
Study NCT02455050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboxymethylcellulose Sodium Based Eye Drops
Description: 1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.
Study NCT02455050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systane® Gel Drops
Description: 1 to 2 drops of Systane® Gel Drops in each eye.
Study NCT02455050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Genteal® Lubricant Gel Drops
Description: 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
Study NCT01783548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP Nasal Aerosol
Study NCT01783548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01326676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill: Red Heart Pill
Description: The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
Study NCT01326676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual medication
Description: Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Study NCT00324740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00324740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study NCT04644965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CombynTM Function & Spaces ECG
Description: Multi-frequency impedance measurement to assess the muscle and fat mass
Study NCT04644965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Taking
Description: Sampling of blood of the finger pad to assess liver function
Study NCT04644965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spiroergometry
Description: Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
Study NCT04644965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dordel Koch Test (DKT)
Description: Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
Study NCT04644965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound for abdominal wall muscles
Study NCT04644965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stance and gait analyses
Description: Stance and gait analyses for measuring the core stability
Study NCT00653328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atrasentan hydrochloride
Description: Atrasentan 10 mg orally everyday continuously beginning on Day 1.
Study NCT00653328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxil
Description: 50 mg/m2 intravenously every 28 days
Study NCT04315597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laif® 900, BAY98-7108
Description: 1 x daily, 1 tablet, 900 mg
Study NCT04315597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 x daily, 1 tablet, 900 mg
Study NCT03732521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational therapy
Description: educational intervention to the caregiver and individualization according to their family and social context
Study NCT02882022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
Study NCT04019210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MODIFIED TRABECULECTOMY
Description: Rectangular scleral flap
Study NCT03012594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
Study NCT00278863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Study NCT00701675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 50 or 100 mg
Description: 50mg or 100mg matching placebo
Study NCT04774328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 (vocacapsaicin)
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Study NCT04774328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Study NCT02790203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAIDS
Study NCT00278863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT02384993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity
Description: This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
Study NCT01810380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily as tablets and capsules, orally
Study NCT01810380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2-4 mg/day, once daily, tablets, orally
Study NCT01810380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine extended release
Description: 400-800 mg/day, once daily, encapsulated tablets, orally
Study NCT01482572 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Description: percutaneous lung biopsy and aspiration
Study NCT04486612 — intervention group
Intervention type: OTHER
Intervention: spinal anesthesia
Description: prospective observational study
Study NCT01126684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg of atorvastatin once daily for six months
Study NCT01126684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily for six months
Study NCT01617928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib (ABT-888)
Description: Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
Study NCT01617928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered on Day 3 of each cycle, intravenously.
Study NCT01617928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered on Day 3 of each cycle, intravenously.
Study NCT03491969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid(α-LA)
Description: 200 mg, po, tid
Study NCT03491969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 200 mg, po, tid
Study NCT02944513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quell
Study NCT00531908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: furosemide
Study NCT02818270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
Study NCT02818270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
Study NCT01154907 — intervention group
Intervention type: DRUG
Intervention: Praziquantel
Description: One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg Piperaquine phosphate
Description: 480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 640 mg Piperaquine phosphate
Description: 640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg OZ 439
Description: 200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg OZ 439
Description: 400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg OZ 439
Description: 800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960 mg PQP
Description: 960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study NCT03542149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg PQP
Description: 320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study NCT02356328 — intervention group
Intervention type: DEVICE
Intervention: NovaTears® Eye Drops
Description: Topical eye drops for lubrication of the ocular surface
Study NCT02953067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and internal fixation
Description: Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
Study NCT02953067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary arthrodesis
Description: Primary arthrodesis versus ORIF
Study NCT02953067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment versus open reduction and internal fixation
Study NCT03006900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates
Study NCT03006900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage
Study NCT03006900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage
Study NCT01234519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: 128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
Study NCT01234519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108 at MTD
Description: 2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
Study NCT02398721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fine Needle Aspiration Cytology
Study NCT02435095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance treatment
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Study NCT02435095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent treatment
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Study NCT01584453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
Study NCT01584453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Placebo
Description: The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
Study NCT01053234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardised meals
Study NCT03892993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Use decision aid
Study NCT03892993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03857061 — intervention group
Intervention type: DEVICE
Intervention: smartphone, smartwatch, WearCOPDv2 application
Description: WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~1. Data collection service~2. Participant user interface
Study NCT01492036 — intervention group
Intervention type: OTHER
Intervention: Blood Tests
Description: If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
Study NCT01492036 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time.
Study NCT02381353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Intraoperative orbital injection of local pain medication
Study NCT02381353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intraoperative orbital injection of local pain medication
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic SCT
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic SCT
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02003222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT03955055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Capsule Endoscopy
Description: Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
Study NCT02707601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02790203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02707601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/R/TAF
Description: 200/25/25 mg FDC tablet administered orally once daily
Study NCT02003222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00603668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: milatuzumab
Description: two or three times a week dosing of hLL1 for a total of 4 weeks
Study NCT01939652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive VS Standard Fluid Regime
Study NCT01939652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drag: Crystalloids and Colloids
Study NCT04193098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL
Description: CTL injection
Study NCT04193098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab injection
Study NCT04527705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical root canal retreatment
Description: Non-surgical root canal retreatment
Study NCT02019329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily administration from Days 1-12
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV
Study NCT02707601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT03696446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Cardiac Rehabilitation Program
Description: This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02003222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV